Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17654701 | 1.00 | S1PR1 (0.52) | S1PR1THRATHRBMRGPRX4ALDH1A1 | |
| SCHEMBL23578526 | 0.94 | MRGPRX4 (0.50) | S1PR1THRATHRBMRGPRX4CTSS | |
| SCHEMBL17208952 | 0.87 | S1PR1 (0.47) | S1PR1THRATHRBMRGPRX4ALDH1A1 | |
| SCHEMBL6248816 | 0.84 | MRGPRX4 (0.55) | S1PR1THRATHRBMRGPRX4CTSS | |
| SCHEMBL10088897 | 0.84 | CTSS (0.55) | MRGPRX4CTSSCTSKARSSTR4 | |
| SCHEMBL1579372 | 0.82 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EHTTL3MBTL1 | |
| SCHEMBL17654321 | 0.81 | ALDH1A1 (0.50) | S1PR1THRATHRBALDH1A1HPGD | |
| SCHEMBL15924404 | 0.81 | ALDH1A1 (0.50) | S1PR1THRATHRBALDH1A1HPGD | |
| SCHEMBL11624971 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HPGDKDM4EHTTL3MBTL1 | |
| SCHEMBL4201247 | 0.81 | AR (0.48) | MRGPRX4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-25 | — | — | US | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3201181-B1 | SPHINGOSINE KINASE INHIBITORS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3201181-B1 | SPHINGOSINE KINASE INHIBITORS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHYNKX THERAPEUTICS, LLC | 2020-10-01 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| CN-101522625-A | Chemical compounds | PRAECIS PHARM INC (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-2046746-A2 | CHEMICAL COMPOUNDS | Praecis Pharmaceuticals Incorporated (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | S1PR1 4/4885THRA 3495/4885THRB 2745/4885 |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | S1PR1 4/4885THRA 3495/4885THRB 2745/4885 |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | S1PR1 4/4885THRA 3495/4885THRB 2745/4885 |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885THRA 1049/4885THRB 909/4885 |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | S1PR1 4/4885THRA 3495/4885THRB 2745/4885 |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | CD4, ICOS, NFATC1 | S1PR1 12/4885THRA 767/4885THRB 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.